DDInter381 DDInter1658
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cinacalcet {u} (Compound) resembles {v} (Compound) Floctafenine
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Cinacalcet {u} (Compound) binds {v} (Gene) CASR
Cinacalcet {u} (Compound) palliates {v} (Disease) chronic kidney failure
Cinacalcet {u} (Compound) is included by {v} (Pharmacologic Class) Increased Calcium-sensing Receptor Sensitivity
Cinacalcet {u} (Compound) causes {v} (Side Effect) Dyspepsia
Cinacalcet (Compound) resembles Floctafenine (Compound)
Cinacalcet (Compound) resembles Duloxetine (Compound)
Cinacalcet (Compound) binds CASR (Gene)
Cinacalcet (Compound) palliates chronic kidney failure (Disease)
Cinacalcet (Compound) is included by Increased Calcium-sensing Receptor Sensitivity (Pharmacologic Class)
Cinacalcet (Compound) causes Dyspepsia (Side Effect)